Small Pharma Stock Revenue
Small Pharma fundamentals help investors to digest information that contributes to Small Pharma's financial success or failures. It also enables traders to predict the movement of Small OTC Stock. The fundamental analysis module provides a way to measure Small Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Small Pharma otc stock.
Small |
Small Pharma OTC Stock Revenue Analysis
Small Pharma's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Small Pharma reported 0.0 of revenue. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Small Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Small Pharma's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Small Pharma could also be used in its relative valuation, which is a method of valuing Small Pharma by comparing valuation metrics of similar companies.Small Pharma is currently under evaluation in revenue category among its peers.
Small Fundamentals
Return On Equity | -0.78 | |||
Return On Asset | -0.41 | |||
Current Valuation | 24.67 M | |||
Shares Outstanding | 321.56 M | |||
Shares Owned By Insiders | 31.08 % | |||
Shares Owned By Institutions | 3.00 % | |||
Price To Book | 1.15 X | |||
Price To Sales | 69,846 X | |||
Gross Profit | 45 K | |||
EBITDA | (22.47 M) | |||
Net Income | (22.27 M) | |||
Cash And Equivalents | 27.15 M | |||
Cash Per Share | 0.08 X | |||
Current Ratio | 6.62 X | |||
Book Value Per Share | 0.06 X | |||
Cash Flow From Operations | (16.23 M) | |||
Earnings Per Share | (0.06) X | |||
Number Of Employees | 10 | |||
Market Capitalization | 27.33 M | |||
Total Asset | 45.57 M | |||
Net Asset | 45.57 M |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Small OTC Stock
If you are still planning to invest in Small Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Small Pharma's history and understand the potential risks before investing.
Commodity Directory Find actively traded commodities issued by global exchanges | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |